Merck & Co., Inc. (NYSE:MRK) Stock Has Consensus Target Price of $146.36 According to Brokerages

Merck & Co., Inc. (NYSE:MRK) has received an average rating of “Moderate Buy” from the twenty-seven research firms that are covering the company, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $151.92.

Several equities analysts have recently weighed in on MRK shares. BMO Capital Markets raised their target price on Merck & Co., Inc. from $142.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, August 20th. Jefferies Financial Group increased their price objective on Merck & Co., Inc. from $152.00 to $175.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. TD Cowen increased their price objective on Merck & Co., Inc. from $137.00 to $155.00 and gave the company a “hold” rating in a research note on Wednesday, September 23rd. Morgan Stanley lowered their target price on shares of Merck & Co., Inc. from $179.00 to $177.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 7th. Finally, Royal Bank Of Canada dropped their target price on shares of Merck & Co., Inc. from $150.00 to $145.00 and set a “sector perform” rating for the company in a report on Monday.

Merck & Co., Inc. Stock Performance

NYSE:MRK opened at $145.49 on Tuesday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. The company has a fifty day moving average of $144.25 and a two-hundred day moving average of $128.57. The stock has a market capitalization of $358.94 billion, a PE ratio of 116.39, a P/E/G ratio of 6.58 and a beta of 0.21. Merck & Co., Inc. has a fifty-two week low of $82.01 and a fifty-two week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter last year, the business earned $2.13 earnings per share. The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts forecast that Merck & Co., Inc. will post 2.66 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. Merck & Co., Inc.’s payout ratio is presently 272.00%.

Insider Activity at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Maraldo sold 18,706 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares in the company, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president owned 36,613 shares in the company, valued at approximately $4,942,755. This represents a 21.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock worth $29,977,783 in the last 90 days. 0.17% of the stock is owned by insiders.

Institutional Trading of Merck & Co., Inc.

Several large investors have recently added to or reduced their stakes in MRK. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth $26,000. Bullseye Investment Management LLC acquired a new stake in shares of Merck & Co., Inc. in the 2nd quarter valued at $27,000. Horizons Wealth Management bought a new stake in shares of Merck & Co., Inc. during the third quarter worth $30,000. Graney & King LLC raised its position in shares of Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares during the last quarter. Finally, Montgomery Financial Services LLC bought a new stake in shares of Merck & Co., Inc. during the second quarter worth $41,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported positive Phase III results for their personalized mRNA cancer-vaccine program. Reports of a planned U.S.-led, NIH-backed initiative to accelerate personalized cancer-vaccine research could further improve sentiment toward Merck’s vaccine pipeline and partnership prospects. Merck could be below fair value on Phase III cancer vaccine results
• Positive Sentiment: Remigromig achieved the statistical threshold for non-inferiority against Lucentis in diabetic macular edema, and Merck described its safety profile as manageable. The results support potential regulatory discussions for the ophthalmology candidate, although the commercial opportunity remains uncertain. Remigromig late-stage trial data
• Neutral Sentiment: Citigroup raised its Merck price target from $125 to $145 but maintained a Neutral rating, placing its target roughly in line with the prevailing share price. Royal Bank of Canada instead cut its target from $150 to $145 and kept a Sector Perform rating, signaling limited near-term valuation upside. Royal Bank of Canada Merck forecast
• Negative Sentiment: Jefferies reduced its peak-sales forecast for remigromig by 60% after detailed BRUNELLO trial results showed smaller numerical vision improvements than the established rival and raised safety concerns. Although the trial met its non-inferiority endpoint, the weaker efficacy profile could reduce the drug’s eventual market share and valuation contribution. Jefferies cuts remigromig sales forecast

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.